Virtual Library
Start Your Search
Sonja Badovinac
Author of
-
+
P1.09 - Pathology (ID 173)
- Event: WCLC 2019
- Type: Poster Viewing in the Exhibit Hall
- Track: Pathology
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
-
+
P1.09-10 - Molecular Immunocytochemistry in Various NSCLC Samples Prepared as Non-Cell Block Cytology (Now Available) (ID 1992)
09:45 - 18:00 | Author(s): Sonja Badovinac
- Abstract
Background
Molecular prognostic-predictive immunocytochemistry is obligatory for therapy decision in NSCLC patients. Immunocytochemistry on cell blocks FFPE cytology is preferred because of some validation advantages, but is not always sufficient in terms of samples acquisition and cell number adequacy. Aim of the study is to compare molecular immunocytochemistry expression between cytology samples obtained with bronchoscopy (bronchial washing/brushings and transbronchial fine needle aspirations) and other cytology samples such as pleural effusion, FNA of peripheral lymph nodes and skin nodules and transthoracic FNA/biopsy; all prepared as non-cell block cytology.
Method
We compared archive records of the 1109 immunocytochemistry (ICC) results of ALK, ROS1 and PD-L1 expression in carcinoma cells in relation to specimen type (bronchoscopic and non-bronchoscopic samples) prepared as smears and cytospins at our institution over a one-year period.
Result
Air dried cytology smears and cytospins of NSCLC samples were stained with Anti-ALK Clone D5F3, Cell Signaling, appendix positive control; Anti-ROS1 Clone D4D6 Cell Signaling, HCC-78 cell line positive control and Anti-PD-L1, Clone 22C3, Dako, placenta imprint positive control; EnVision detection system on Immunocytochemistry Autostainer. PD-L1 protein expression was scored using Tumor Proportion Score (TPS) with positive cut-off of ≥1%, membrane staining. The slides were routinely examined and scored by two cytologists. Internal and external quality control were performed on FFPE cell blocks and histology slides with corresponding Ventana antibodies and staining systems.
Out of 1109 results, 440 were ALK ICC results, 111 ROS1 and 558 were PD-L1 ICC staining results. Among them 314/440 (71, 36%) ALK, 75/111 (67,57%) ROS1 and 392/558 PD-L1 ICC (70,25%) were in bronchoscopic samples and 126/440 (28,64%) ALK, 36/111 (32,43%) ROS1 and 166/558 (29,75%) PD-L1 ICC were in various non-bronchoscopic samples. Comparison in ALK, ROS1 and PD-L1 ICC distribution between two groups of samples showed no statistical significant difference among groups (X2 test, df 2, p=0,730). Positive ALK and ROS1 numbers were in observed range, but insufficient for statistical analysis. PD-L1 ICC scored results were in total of 392 samples collected during bronchoscopy and 166 of various other non-bronchoscopic samples: 88 were obtained by FNA of peripheral lymph nodes and skin nodules, 38 by transthoracic FNA/biopsy and 40 pleural effusions. PD-L1 ICC scored negative in total of 281/558 (50,36%) samples, 191 bronchoscopic and 90 non-bronchoscopic. PD-L1 ICC scored positive in total of 277/558 (47,11%) samples of which 201 were obtained with bronchoscopy and 76 of samples collected with other methods. Among of total PD-L1 positive smears, 128 were PD-L1 positive ≥ 50%; 90/128 (70,31%) were bronchoscopical samples and 38/128 (29,7%) other samples. Comparison in PD-L1 expression between two groups of samples showed no statistical significant difference among groups (X2 test, df 1, p=0,236). Comparison between two groups of PD-L1 positive ≥ 50% showed no statistical significant difference among sample groups (X2 test, df 1, p=0,436).
Conclusion
There were no statistical significant differences in molecular ALK, ROS1 and PD-L1 immunocytochemistry results between samples collected during bronchoscopy and non-bronchoscopic samples prepared as non-cell block cytology. PD-L1 scoring results were also independent of cytology sample type in our study.
-
+
P2.05 - Interventional Diagnostic/Pulmonology (ID 168)
- Event: WCLC 2019
- Type: Poster Viewing in the Exhibit Hall
- Track: Interventional Diagnostics/Pulmonology
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
-
+
P2.05-18 - Tissue Sampling and Prognostic Biomarkers Analysis of Peripheral Lung Tumors Using R-EBUS. Single Centre Retrospective Study (ID 1934)
10:15 - 18:15 | Presenting Author(s): Sonja Badovinac
- Abstract
Background
Tissue sampling of peripheral pulmonary neoplasms for patohistology and analysis of prognostic biomarkers can be challenging. Radial endobronchial ultrasound (R-EBUS) is one of sophisticated guiding bronchoscopic modalities used for more precise localisation of the peripheral lesions. Novel therapeutic strategies rely on different prognostic biomarkers status. In this retrospective study we explored sufficiency of specimens for patohistology and prognostic biomarkers analysis obtained by ultra-thin bronchoscope combined with R-EBUS.
Method
Retrospective analysis of bronchoscopy cases positive on malignancies when R-EBUS was used for visualisation of peripheral tumors and tissue was obtained with commercial sampling kit.
Result
80 consecutive cases with pathologic ultrasound pattern found with R-EBUS were analysed. Malignant disease was diagnosed in 49 cases (61%). Mean lesion diameter was 24mm (range 15 to 40mm). The most common histology types were adenocarcinoma, squamous cell carcinoma and small cell carcinoma – 78%, 12% and 4% respectively. Extrathoracic malignancies were diagnosed in 6% of cases. The tissue was sufficient for prognostic biomarker analysis in 91% of the cases – whereas EGFR, ALK, ROS1 and PDL-1 testing was performed for adenocarcinomas and PDL-1 for squamous cell lung carcinomas. In 9% of cases samples were sufficient for histologic typing only.
Conclusion
Bronchoscopy with R-EBUS is useful diagnostic method for peripheral lung tumours. Obtained samples can be used for histology subtyping and prognostic biomarkers analysis in most cases as well.
